Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Hepion Pharmaceuticals Inc
NASDAQ HEPA
Data sourced from
and
and
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2023 was -10,189,153.56, a -15.85% change year over year.
-
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2022 was -8,795,180.56, a -59.91% change year over year.
-
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2021 was -5,499,975.95, a -229.81% change year over year.
-
Hepion Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2020 was -1,667,636.00, a -104.11% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: HEPA
| CEO | Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. |
| IPO Date | Feb. 11, 2014 |
| Location | United States |
| Headquarters | 399 Thornall Street, Edison, NJ, United States, 08837 |
| Employees | 22 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Key trends
Similar companies
AVROBIO Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email